Synlogic (SYBX) Competitors $1.31 +0.01 (+0.85%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. QNCX, UNCY, CUE, MRSN, IOBT, ACHL, OPTN, VOR, KRON, and STTKShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Quince Therapeutics (QNCX), Unicycive Therapeutics (UNCY), Cue Biopharma (CUE), Mersana Therapeutics (MRSN), IO Biotech (IOBT), Achilles Therapeutics (ACHL), OptiNose (OPTN), Vor Biopharma (VOR), Kronos Bio (KRON), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Quince Therapeutics Unicycive Therapeutics Cue Biopharma Mersana Therapeutics IO Biotech Achilles Therapeutics OptiNose Vor Biopharma Kronos Bio Shattuck Labs Synlogic (NASDAQ:SYBX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment. Is SYBX or QNCX more profitable? Quince Therapeutics' return on equity of -53.27% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% Quince Therapeutics N/A -53.27%-22.73% Which has more volatility & risk, SYBX or QNCX? Synlogic has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Do institutionals and insiders believe in SYBX or QNCX? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings & valuation, SYBX or QNCX? Quince Therapeutics has lower revenue, but higher earnings than Synlogic. Quince Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,913.76-$57.28M-$2.51-0.52Quince TherapeuticsN/AN/A-$31.39M-$1.24-1.08 Does the media favor SYBX or QNCX? In the previous week, Quince Therapeutics had 13 more articles in the media than Synlogic. MarketBeat recorded 14 mentions for Quince Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.87 beat Quince Therapeutics' score of 0.04 indicating that Synlogic is being referred to more favorably in the media. Company Overall Sentiment Synlogic Very Positive Quince Therapeutics Neutral Does the MarketBeat Community believe in SYBX or QNCX? Synlogic received 322 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Quince TherapeuticsOutperform Votes9100.00% Underperform VotesNo Votes Do analysts rate SYBX or QNCX? Quince Therapeutics has a consensus price target of $8.00, indicating a potential upside of 497.01%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryQuince Therapeutics beats Synlogic on 11 of the 17 factors compared between the two stocks. Remove Ads Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.31M$6.90B$5.63B$8.13BDividend YieldN/A2.73%4.55%4.00%P/E Ratio-0.317.1524.5019.08Price / Sales1,913.76226.93385.2994.58Price / CashN/A65.6738.1634.64Price / Book0.286.486.954.36Net Income-$57.28M$142.41M$3.20B$247.23M7 Day Performance0.69%-3.39%-2.42%-0.61%1 Month Performance-5.49%-5.34%2.18%-5.12%1 Year Performance-26.46%-7.01%12.85%3.60% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic1.784 of 5 stars$1.31+0.8%N/A-29.2%$15.31M$8,000.00-0.3180Positive NewsGap DownQNCXQuince Therapeutics2.3066 of 5 stars$1.38-4.2%$9.50+588.4%+14.2%$60.72MN/A-1.1160Earnings ReportAnalyst ForecastShort Interest ↓News CoveragePositive NewsUNCYUnicycive Therapeutics2.7977 of 5 stars$0.58-0.7%$5.33+818.0%-58.2%$60.31M$680,000.00-0.609Upcoming EarningsNews CoverageGap UpCUECue Biopharma4.3211 of 5 stars$0.95-0.7%$4.75+400.0%-46.4%$60.18M$9.53M-1.0660MRSNMersana Therapeutics4.4477 of 5 stars$0.48+3.0%$4.25+787.3%-89.5%$59.70M$40.50M-0.79150Short Interest ↓Positive NewsIOBTIO Biotech2.7461 of 5 stars$0.90+2.4%$9.33+937.0%-32.4%$59.29MN/A-0.6630Short Interest ↑Gap UpACHLAchilles Therapeutics3.2463 of 5 stars$1.44+0.7%$4.00+177.8%N/A$59.18MN/A-0.87250OPTNOptiNose2.673 of 5 stars$5.88+9.7%$16.67+183.4%-59.2%$59.15M$75.67M-1.40190VORVor Biopharma2.03 of 5 stars$0.86-3.9%$11.36+1,220.1%-58.5%$59.08MN/A-0.52140Gap UpKRONKronos Bio3.4275 of 5 stars$0.95+1.1%$1.63+71.1%-30.7%$57.32M$9.86M-0.66100Short Interest ↓News CoverageSTTKShattuck Labs2.6005 of 5 stars$1.17-1.7%$7.50+541.0%-87.0%$55.86M$6.44M-0.76100Gap Up Remove Ads Related Companies and Tools Related Companies Quince Therapeutics Competitors Unicycive Therapeutics Competitors Cue Biopharma Competitors Mersana Therapeutics Competitors IO Biotech Competitors Achilles Therapeutics Competitors OptiNose Competitors Vor Biopharma Competitors Kronos Bio Competitors Shattuck Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYBX Stock Free SYBX Stock Alerts